Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform
Formal patent issuance still requires an issue-fee payment and remaining formalities before the final claims determine protection.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Victory Square Technologies (VSQTF) announced that portfolio company Insu Therapeutics received a U.S. patent allowance for its peptide-delivery technology. The application covers delivery through the mouth’s lining, supporting InsuTab, an investigational insulin formulation, and BuccaGLP, an investigational semaglutide formulation. It has cleared substantive examination; issuance still requires an issue-fee payment and remaining formalities. Protection will depend on the final issued claims.
Insu holds an exclusive worldwide UBC licence to develop, commercialize and sublicense the technology. Hydreight previously invested C$300,000 in Insu and disclosed exclusive U.S. distribution rights, subject to successful development and regulatory approvals. Insu has completed laboratory, cell-culture and rat proof-of-concept studies for buccal insulin. Neither candidate is approved for commercial sale; patent allowance is not regulatory approval.
Positive
- Minor pointU.S. patent allowance advances portfolio company Insu’s intellectual-property foundation after substantive examination.
- Minor pointExclusive worldwide UBC licence gives Insu development, commercialization and sublicensing rights.
- Minor pointC$300,000 Hydreight investment, completed March 13, 2026, provided funding to portfolio company Insu.
- Minor point. Forward-looking: it has not happened yet and may not happen.Exclusive U.S. distribution rights previously disclosed by Hydreight establish a potential channel for Insu’s peptide therapeutics.
- Minor pointLaboratory, cell-culture and rat studies completed at UBC provide proof-of-concept work for Insu’s buccal insulin program.
- Minor point. Forward-looking: it has not happened yet and may not happen.Regulatory engagement preparations accompany continued Victory Square support for Insu’s development programs.
Negative
- Minor pointPatent issuance remains pending, requiring payment of the issue fee and completion of remaining formalities.
- Minor point. Forward-looking: it has not happened yet and may not happen.Patent protection scope will be determined by the final issued claims.
- Minor point. Forward-looking: it has not happened yet and may not happen.U.S. distribution depends on successful development and regulatory approvals.
- Minor point. Forward-looking: it has not happened yet and may not happen.Product introduction requires product-specific prescribing, pharmacy, manufacturing and operational arrangements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Milestone advances portfolio company's intellectual-property foundation for InsuTab™ and BuccaGLP™, supported by an exclusive worldwide UBC licence and Hydreight's previously disclosed
The allowance advances the intellectual-property foundation behind InsuTab™, Insu's investigational buccal insulin formulation, and BuccaGLP™, its investigational buccal semaglutide formulation. Both programs are being developed to deliver peptide medicines through the lining of the mouth, offering a potential needle-free alternative to injections.
Insu holds an exclusive, worldwide licence from the University of
The patent application has cleared substantive examination. Formal patent issuance remains subject to payment of the required issue fee and completion of remaining formalities.
"Peptide medicines are changing the treatment of diabetes and obesity. How patients take those medicines is an important part of the opportunity," said Shafin Diamond Tejani, Chief Executive Officer of Victory Square Technologies. "Insu is developing a delivery platform with insulin and semaglutide as its first programs. This
A delivery platform with multiple development opportunities
The Notice of Allowance relates to
The application concerns a layered dosage form designed to adhere to the inner cheek and direct the release of a peptide medicine toward the underlying tissue. Insu's approach is intended to support absorption through the mouth's lining rather than relying on gastrointestinal absorption after swallowing. The scope of patent protection will be determined by the final issued claims.
Insu is applying this delivery architecture to two initial programs:
- InsuTab™: an investigational buccal insulin formulation.
- BuccaGLP™: an investigational buccal semaglutide formulation for a GLP-1 medicine used in metabolic disease.
Its exclusive worldwide licence also provides a foundation for pursuing potential licensing and co-development opportunities as the technology progresses.
Designed around practical treatment needs
Insu's development strategy addresses a practical question: how to deliver established peptide medicines in a form that could be easier for patients to incorporate into daily life.
Injectable treatments require needles and associated administration supplies. Certain swallowed peptide formulations require carefully timed dosing around food, beverages and other medicines. Insu is developing its buccal formulations to offer a different route of administration.
Insu reports that its formulation does not require fasting or restrictions on food and drink before or after dosing. Its buccal format is designed to avoid the needles and injection supplies used to administer injectable products. These potential convenience benefits remain subject to further evaluation as the individual candidates advance through development.
Research supporting the initial programs
Insu has completed laboratory, cell-culture and rat studies at UBC as proof-of-concept work for its buccal insulin program. Its buccal semaglutide program applies the same delivery architecture to a GLP-1 medicine.
Research by members of Insu's scientific team was published in Pharmaceutics in September 2023 under the title "Concept for a Unidirectional Release Mucoadhesive Buccal Tablet for Oral Delivery of Antidiabetic Peptide Drugs Such as Insulin, Glucagon-like Peptide 1 (GLP-1), and their Analogs."
The publication describes the scientific rationale for buccal peptide delivery and unidirectional-release formulations. Further studies are required to establish the performance, safety and efficacy of Insu's individual candidates.
"This allowance is an important step in advancing the technology behind InsuTab and BuccaGLP," said Dr. Anubhav Pratap-Singh, Board chair and Co-Founder of Insu Therapeutics. "Our focus is to translate the research into practical needle-free formulations for insulin and semaglutide. The exclusive UBC licence and this patent milestone support that work and our ability to pursue future development partnerships."
Development in an expanding therapeutic market
Insu's initial programs target insulin and GLP-1 medicines used in diabetes and metabolic disease.
Morgan Stanley Research reports approximately
Insu's commercial opportunity will depend on successful development, regulatory approval, manufacturing readiness and adoption of its products.
Connecting innovation with healthcare infrastructure
The relationship between Insu and Hydreight adds a potential distribution channel to Insu's development strategy.
As announced on March 13, 2026, Hydreight completed a
Hydreight operates healthcare infrastructure connecting physicians, pharmacies and patients across all 50 U.S. states. If Insu's candidates successfully complete development and receive the required approvals, that infrastructure could support future
"For VST shareholders, this milestone shows the progress of a business we have helped build around university-developed technology," added Tejani. "Insu is advancing the delivery platform, while Hydreight brings healthcare infrastructure that could support its future distribution. Our focus is to help these businesses turn that foundation into products, partnerships and long-term shareholder value."
Victory Square continues to support Insu as it advances its development programs and prepares for regulatory engagement.
InsuTab and BuccaGLP remain investigational and are not approved for commercial sale. Patent allowance does not establish clinical safety or efficacy or constitute regulatory approval.
On behalf of the Board of Directors
Shafin Diamond Tejani
Chairman & Chief Executive Officer
Victory Square Technologies Inc.
About Insu Therapeutics
Insu Therapeutics Inc. is a
About Victory Square Technologies
Victory Square Technologies Inc. is a venture builder focused on healthcare infrastructure, digital health, artificial intelligence and emerging technology platforms. The Company supports portfolio businesses through capital, strategic guidance and business development as they advance their technologies and build commercial operations.
For more information, visit www.victorysquare.com.
References
Pratap-Singh A., Guo Y., Baldelli A. and Singh A. Pharmaceutics. 2023;15(9):2265. DOI: 10.3390/pharmaceutics15092265.
Morgan Stanley Research. "Obesity Drugs Are Scaling Fast." April 22, 2026.
Hydreight Technologies Inc. "Hydreight Technologies Closes Strategic Investment in Insu Therapeutics." March 13, 2026.
Forward-Looking Information
This release contains forward-looking information concerning anticipated patent issuance and scope, Insu's development programs, potential product benefits, regulatory engagement and approvals, manufacturing readiness, licensing and co-development opportunities, potential U.S. distribution through Hydreight, shareholder value and third-party market forecasts.
Such information reflects current expectations and assumptions, including that Insu can obtain sufficient funding, generate satisfactory development results, secure required approvals and maintain relevant intellectual-property and contractual rights, and that suitable manufacturing and distribution arrangements can be established.
Forward-looking information is subject to risks and uncertainties, including patent issuance and scope, development outcomes, safety and efficacy findings, funding availability, regulatory requirements, manufacturing capacity, competition, market adoption and the ability to implement commercial arrangements. Actual results may differ materially. There is no assurance that Insu's candidates will receive regulatory approval, achieve commercial success or generate revenue for Insu, Hydreight or Victory Square. Third-party market forecasts are estimates and may not be realized.
Readers should also review the risk factors in the Company's filings on SEDAR+. Except as required by applicable law, the Company undertakes no obligation to update forward-looking information.
View original content to download multimedia:https://www.prnewswire.com/news-releases/victory-square-announces-us-patent-allowance-for-insu-therapeutics-needle-free-insulin-and-glp-1-delivery-platform-302901712.html
SOURCE Victory Square Technologies Inc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Insu patent allowance announced by Victory Square (VSQTF) cover?
The allowance covers an application for buccal peptide-delivery technology supporting InsuTab and BuccaGLP. U.S. Patent Application No. 18/513,373 concerns a layered dosage form designed to adhere to the inner cheek and direct peptide release toward the underlying tissue. Formal issuance remains pending, and the final issued claims will determine protection.
Are InsuTab and BuccaGLP approved following Victory Square’s patent announcement?
Neither InsuTab nor BuccaGLP is approved for commercial sale. Both remain investigational. Patent allowance does not establish clinical safety or efficacy and does not constitute regulatory approval.
What does Insu say about food restrictions for its needle-free formulations?
Insu reports that its formulation does not require fasting or restrictions on food and drink before or after dosing. These potential convenience benefits remain subject to further evaluation as the individual candidates advance through development.